Trimel Pharmaceutica (TRLPF) 0.6210 $TRLPF
Trimel Reports Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 6:34PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three and twelve month periods ended December 31, 2013.
Trimel to Report Financial Results for 2013 and Host Conference Call to Update Investors
Marketwire - Thu Feb 27, 3:46PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its financial results for the 3 month and 12 month periods ended December 31, 2013 on Wednesday, March 5th 2014 after market close.
Trimel Announces Closing of $10.5 Million Private Placement of Common Shares
Marketwire - Fri Feb 21, 2:46PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the previously disclosed private placement of 14,829,676 common shares ("Common Shares"), in aggregate, to First Generation Capital Inc. and West Face Long Term Opportunities Global Master L.P. for total gross proceeds of $10,543,000 has been completed.
First Generation Capital Inc. Acquires Shares of Trimel Pharmaceuticals Corporation
Marketwire - Wed Feb 19, 5:43PM CST
Mr. Ian Ihnatowycz, announced today that he has entered into an agreement to acquire 9,203,797 common shares of Trimel Pharmaceuticals Corporation (the "Issuer") at $0.711 per share through his private investment holding company First Generation Capital Inc. The purchase will be made on a private placement basis from the Issuer and is expected to close next week.
Trimel Announces $10.5 Million Private Placement of Common Shares
Marketwire - Wed Feb 19, 2:38PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that it has entered into subscription agreements in connection with a private placement of 14,829,676 common shares ("Common Shares") for aggregate gross proceeds in the amount of $10,543,900. The issue price of the Common Shares will be $0.711 per share, equal to the "market price" of the Common Shares as of the date of acceptance of the applicable subscriptions (as calculated in accordance with the rules of the Toronto Stock Exchange ("TSX")). The Common Shares will be subject to a hold period under applicable securities laws, which will expire four months plus one day from the date of closing.
IIROC Trade Halt - Trimel Pharmaceuticals Corporation
Newsfile Corp - Wed Feb 19, 2:38PM CST
The following issues have been halted by IIROC:
Trimel Announces Appointment of New Vice President, Scientific Affairs
Marketwire - Thu Jan 23, 4:05PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) is pleased to announce the appointment of Dr. Nathan Bryson to the position of Vice President, Scientific Affairs. Dr. Bryson will replace Mr. Wayne Kreppner who has elected to pursue other opportunities. Dr. Bryson will be responsible for all areas of the Company's research and development activities as well as leading the clinical, regulatory affairs, and manufacturing functions.
Trimel Provides Update Regarding CompleoTRT(TM) FDA Review
Marketwire - Fri Jan 17, 6:56AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT(TM) new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
Trimel Announces Appointment of Tom Rossi to Its Board of Directors
Marketwire - Thu Jan 16, 4:08PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the appointment of Mr. Tom Rossi, the company's President and Chief Executive Officer, to its Board of Directors, effective January 21, 2014.
Trimel Completes Enrollment of Tefina(TM) Ambulatory Study
Marketwire - Tue Jan 14, 4:00PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) is pleased to announce that it has completed enrollment of its ongoing Tefina(TM) Phase II clinical trial. Tefina(TM) is being developed and clinically tested as a possible treatment for women suffering from Female Orgasmic Disorder.
Trimel Announces Retirement of Chair and Appointment of New Chair
Marketwire - Fri Jan 10, 4:05PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the retirement of Mr. Bruce Brydon as Chair of the Board of Directors and as a Director.
Trimel Reports Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Wed Mar 05, 6:34PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three and twelve month periods ended December 31, 2013.
Trimel to Report Financial Results for 2013 and Host Conference Call to Update Investors
Marketwire - Thu Feb 27, 3:46PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) will report its financial results for the 3 month and 12 month periods ended December 31, 2013 on Wednesday, March 5th 2014 after market close.
Trimel Announces Closing of $10.5 Million Private Placement of Common Shares
Marketwire - Fri Feb 21, 2:46PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the previously disclosed private placement of 14,829,676 common shares ("Common Shares"), in aggregate, to First Generation Capital Inc. and West Face Long Term Opportunities Global Master L.P. for total gross proceeds of $10,543,000 has been completed.
First Generation Capital Inc. Acquires Shares of Trimel Pharmaceuticals Corporation
Marketwire - Wed Feb 19, 5:43PM CST
Mr. Ian Ihnatowycz, announced today that he has entered into an agreement to acquire 9,203,797 common shares of Trimel Pharmaceuticals Corporation (the "Issuer") at $0.711 per share through his private investment holding company First Generation Capital Inc. The purchase will be made on a private placement basis from the Issuer and is expected to close next week.
Trimel Announces $10.5 Million Private Placement of Common Shares
Marketwire - Wed Feb 19, 2:38PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that it has entered into subscription agreements in connection with a private placement of 14,829,676 common shares ("Common Shares") for aggregate gross proceeds in the amount of $10,543,900. The issue price of the Common Shares will be $0.711 per share, equal to the "market price" of the Common Shares as of the date of acceptance of the applicable subscriptions (as calculated in accordance with the rules of the Toronto Stock Exchange ("TSX")). The Common Shares will be subject to a hold period under applicable securities laws, which will expire four months plus one day from the date of closing.
IIROC Trade Halt - Trimel Pharmaceuticals Corporation
Newsfile Corp - Wed Feb 19, 2:38PM CST
The following issues have been halted by IIROC:
Trimel Announces Appointment of New Vice President, Scientific Affairs
Marketwire - Thu Jan 23, 4:05PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) is pleased to announce the appointment of Dr. Nathan Bryson to the position of Vice President, Scientific Affairs. Dr. Bryson will replace Mr. Wayne Kreppner who has elected to pursue other opportunities. Dr. Bryson will be responsible for all areas of the Company's research and development activities as well as leading the clinical, regulatory affairs, and manufacturing functions.
Trimel Provides Update Regarding CompleoTRT(TM) FDA Review
Marketwire - Fri Jan 17, 6:56AM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that the United States Food and Drug Administration ("FDA") has decided to extend the Prescription Drug User Fee Act (PDUFA) target action date for the CompleoTRT(TM) new drug application ("NDA") from February 28, 2014 to May 28, 2014. This will provide the FDA with the required time for a full review of the submission in light of the previously announced decision by the Company to amend its proposed label.
Trimel Announces Appointment of Tom Rossi to Its Board of Directors
Marketwire - Thu Jan 16, 4:08PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the appointment of Mr. Tom Rossi, the company's President and Chief Executive Officer, to its Board of Directors, effective January 21, 2014.
Trimel Completes Enrollment of Tefina(TM) Ambulatory Study
Marketwire - Tue Jan 14, 4:00PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) is pleased to announce that it has completed enrollment of its ongoing Tefina(TM) Phase II clinical trial. Tefina(TM) is being developed and clinically tested as a possible treatment for women suffering from Female Orgasmic Disorder.
Trimel Announces Retirement of Chair and Appointment of New Chair
Marketwire - Fri Jan 10, 4:05PM CST
Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the retirement of Mr. Bruce Brydon as Chair of the Board of Directors and as a Director.
